TRYP Therapeutics Inc
CNSX:TRYP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
TRYP Therapeutics Inc
Research & Development
TRYP Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TRYP Therapeutics Inc
CNSX:TRYP
|
Research & Development
-CA$2.4m
|
CAGR 3-Years
-557%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Research & Development
-$631m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
Cronos Group Inc
TSX:CRON
|
Research & Development
-$4.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Research & Development
-$105.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-152%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Research & Development
-CA$27.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-26%
|
|
|
Devonian Health Group Inc
XTSX:GSD
|
Research & Development
-CA$1.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
TRYP Therapeutics Inc
Glance View
Tryp Therapeutics, Inc. is a pharmaceutical company, which engages in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2020-12-18. The firm is focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The Company’s lead development program, Psilocybin-For-Neuropsychiatric Disorders (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The primary indications for its PFN are in the areas of chronic pain, including fibromyalgia, phantom limb pain and complex regional pain syndrome, and eating disorders, including binge eating and hypothalamic obesity. The firm's product pipeline includes TRP-8802 and TRP-8803. TRP-8803 uses a formulation and route of administration to improve the patient experience. The firm is also engaged in developing a formulation of razoxane for the treatment of soft tissue sarcomas.
See Also
What is TRYP Therapeutics Inc's Research & Development?
Research & Development
-2.4m
CAD
Based on the financial report for Aug 31, 2023, TRYP Therapeutics Inc's Research & Development amounts to -2.4m CAD.
What is TRYP Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-557%
Over the last year, the Research & Development growth was 21%. The average annual Research & Development growth rates for TRYP Therapeutics Inc have been -557% over the past three years .
